Choate Investment Advisors trimmed its stake in Amgen Inc. by 9.0% during Q4, selling 1,579 shares and holding 15,990 shares worth $4.17 million. Meanwhile, other major institutional investors, like ...
The massive pharmacy benefit manager plans to stop requiring coverage authorizations for roughly 80 drugs used to treat ...
Zacks Investment Research on MSN18h
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for ReviewDr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO, /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical ...
Impact Capital Partners LLC recently injected $234,000 into Amgen Inc., acquiring 898 shares in the medical giant. This move ...
On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...
Zacks Investment Research on MSN1d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...
The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...
The fund has already screened over 300 projects and made several investments into new companies to catalyze transformative innovation in biotechnology PARIS– (BUSINESS WIRE)– Sofinnova Partners ...
After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback